NFAP2, a novel cysteine-rich anti-yeast protein from Neosartorya fischeri NRRL 181: isolation and characterization.
Liliána TóthZoltán KeleAttila BoricsLászló G NagyGyörgyi VáradiMáté VirághMiklós TakóCsaba VágvölgyiLászló GalgóczyPublished in: AMB Express (2016)
The increasing incidence of fungal infections and damages due to drug-resistant fungi urges the development of new antifungal strategies. The cysteine-rich antifungal proteins from filamentous ascomycetes provide a feasible base for protection against molds due to their potent antifungal activity on them. In contrast to this, they show no or weak activity on yeasts, hence their applicability against this group of fungi is questionable. In the present study a 5.6 kDa anti-yeast protein (NFAP2) is isolated, identified and characterized from the ferment broth of Neosartorya fischeri NRRL 181. Based on a phylogenetic analysis, NFAP2 and its putative homologs represent a new group of ascomycetous cysteine-rich antifungal proteins. NFAP2 proved to be highly effective against tested yeasts involving clinically relevant Candida species. NFAP2 did not cause metabolic inactivity and apoptosis induction, but its plasma membrane disruption ability was observed on Saccharomyces cerevisiae. The antifungal activity was maintained after high temperature treatment presumably due to the in silico predicted stable tertiary structure. The disulfide bond-stabilized, heat-resistant folded structure of NFAP2 was experimentally proved. After further investigations of antifungal mechanism, structure and toxicity, NFAP2 could be applicable as a potent antifungal agent against yeasts.
Keyphrases
- saccharomyces cerevisiae
- candida albicans
- drug resistant
- biofilm formation
- multidrug resistant
- high temperature
- oxidative stress
- fluorescent probe
- magnetic resonance
- living cells
- acinetobacter baumannii
- computed tomography
- protein protein
- magnetic resonance imaging
- cell death
- anti inflammatory
- heat stress
- endoplasmic reticulum stress
- replacement therapy
- combination therapy
- pseudomonas aeruginosa
- transition metal